ALISO VIEJO, CA--(Marketwire - Nov 14, 2011) - CNS Response, Inc. (OTCBB: [ CNSO ]) today announced that Poster 106, featured at the 2011 NEI Global Psychopharmacology Congress, highlights the use of PEER Online™ to assist physicians in reducing trial and error medication selection and avoiding possible severe adverse events from medications for non-psychotic patients. The findings are from a retrospective eight-year patient chart review that was conducted by Daniel A. Hoffman, M.D., Deb Arrera, CNS, RXN and Nicole Shadid, M.D.

PEER Online, which builds on CNS Response's original physician-developed database, Referenced-EEG^® (rEEG^®), is a physician-developed information tool aimed at providing fellow physicians with data they can use to improve patient outcomes. PEER Online enables physicians to compare and learn which medication treatments have been effective, and which have been ineffective for their peers in treating patients with similar EEGs.

According to CNS Response Chief Medical Officer, Daniel Hoffman, M.D., "In our review of patient charts from an eight-year period, we found that when physicians used information provided through PEER Online to treat patients, they successfully reduced patient suffering from severe adverse effects, which can be a result of prescribing medications not suited to a patient's neurophysiology. The chart review also showed a decline in reported suicidality, from 26 percent down to 4 percent, when patients were treated using data provided through PEER Online. In addition, we also found that just over 10 percent of the patients actually needed no medication at all. These are significant results that demonstrate the value of PEER Online's data suggesting that objective information combined with clinical judgment can offer safer and better outcomes."

The poster, Using A Referenced-EEG Database to Assist in Predicting Severe Adverse Events and Selecting Medications for Non-Psychotic Patients - A Retrospective Chart Review, was presented Friday, November 11, at the 2011 NEI Global Psychopharmacology Congress, held in Colorado Springs, Colorado.

About CNS Response
CNS Response provides reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorder. The company recently launched the Psychiatric EEG Evaluation Registry, or PEER Online™, a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through an EEG. PEER Online™ builds on the company's original physician-developed database, Referenced-EEG^® (rEEG^®). Avoiding trial and error pharmacotherapy, the dominant approach for psychiatric treatment, is the objective of PEER Online™.

To read more about the benefits of this patented technology for patients, physicians and payers, please visit [ www.cnsresponse.com ]. Medical professionals interested in learning more can contact CNS Response at [ PEERinfo@cnsresponse.com ].

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.